Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BHMT | Q93088 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 5/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18704287 | 1.00 | BHMT (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL9460828 | 1.00 | BHMT (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL8569864 | 0.93 | BHMT (0.43) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL8984477 | 0.91 | GPR84 (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL8984580 | 0.91 | GPR84 (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL8984636 | 0.91 | GPR84 (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL8984397 | 0.91 | GPR84 (0.44) | BHMTCAMK2ABLMGPR84FFAR1 | |
| SCHEMBL14360558 | 0.87 | BHMT (0.48) | BHMTBLMGPR84ACE2SLC22A6 | |
| SCHEMBL425046 | 0.87 | BHMT (0.48) | BHMTBLMGPR84ACE2SLC22A6 | |
| SCHEMBL7532145 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113004205-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2024-07-02 | — | — | CN | disclosed |
| US-11912681-B2 | Crystalline and salt forms of PPAR agonist compounds | MITOBRIDGE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | Astellas Engineered Small Molecules US, Incorporated | 2023-11-23 | — | — | US | disclosed |
| US-20230257360-A1 | CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS | Astellas Engineered Small Molecules US, Incorporated | 2023-08-17 | — | — | US | disclosed |
| EP-3795566-B1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | MITOBRIDGE INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | MITOBRIDGE, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-109843857-B | Crystalline and salt forms of PPAR agonist compounds | 米托布里奇公司 | 2023-01-06 | — | — | CN | disclosed |
| US-11530192-B2 | Crystalline and salt forms of PPAR agonist compounds | MITOBRIDGE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| CN-109789117-B | Method for treating acute kidney injury | 米托布里奇公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-109071459-B | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | 米托布里奇公司 | 2022-08-16 | — | — | CN | disclosed |
| EP-1622962-B1 | TOUGHENED POLYOXYMETHYLENE-POLY(LACTIC ACID) COMPOSITIONS | DU PONT (US) | 2006-07-05 | — | — | EP | disclosed |
| EP-1622962-A1 | TOUGHENED POLYOXYMETHYLENE-POLY(LACTIC ACID) COMPOSITIONS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-02-08 | — | — | EP | disclosed |
| CN-1701082-A | Toughened polyoxymethylene-poly(lactic acid) compositions | DU PONT (US) | 2005-11-23 | — | — | CN | disclosed |
| US-6943214-B2 | Toughened polyoxymethylene-poly(lactic acid) compositions | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005059031-A1 | TOUGHENED POLY(LACTIC ACID) COMPOSITIONS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050131120-A1 | Toughened poly(lactic acid) compositions | PERFORMANCE MATERIALS NA, INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2004101642-A1 | TOUGHENED POLYOXYMETHYLENE-POLY(LACTIC ACID) COMPOSITIONS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040230001-A1 | Toughened polyoxymethylene-poly(lactic acid) compositions | GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT | 2004-11-18 | — | — | US | disclosed |
| US-5227090-A | Acrylic ester polymers | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-13 | — | — | US | disclosed |
| US-4140712-A | 20-Hydroxy-prostaglandins | ONO PHARMACEUTICAL COMPANY (JP) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530192-B2 | Crystalline and salt forms of PPAR agonist compounds | PPARD, PPARA, PPARG | BHMT 4414/4885CAMK2A 706/4885BLM 3293/4885 |
| US-11912681-B2 | Crystalline and salt forms of PPAR agonist compounds | PPARD, PPARA, PPARG | BHMT 4414/4885CAMK2A 706/4885BLM 3293/4885 |
| US-20230373948-A1 | PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | PPARG, PPARD, PPARA | BHMT 2630/4885CAMK2A 1276/4885BLM 2009/4885 |
| US-11578052-B2 | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | PPARG, PPARD, PPARA | BHMT 2630/4885CAMK2A 1276/4885BLM 2009/4885 |
| US-20230257360-A1 | CRYSTALLINE AND SALT FORMS OF PPAR AGONIST COMPOUNDS | PPARD, PPARA, PPARG | BHMT 4414/4885CAMK2A 706/4885BLM 3293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.